A method, system and device for predicting drug resistance status
By constructing a predictive model of drug resistance status of JQ1, identifying the ferrodemortization gene and clustering analysis of TNBC cells, the problem of resistance to JQ1 in TNBC treatment was solved, and sensitization drugs were screened out, providing new treatment strategies and improving Treatment effect.
Patent Information
- Application Number
- CN202410809417.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-06-21
AI Technical Summary
Triple-negative breast cancer (TNBC) develops resistance to BET bromodomain inhibitors (BBDI) such as JQ1 during the treatment process, resulting in limited therapeutic effects. It is difficult for the prior art to effectively identify drug resistance mechanisms and sensitization drugs.
Construct the JQ1 drug resistance status prediction model, obtain differentially expressed genes of JQ1 sensitive and drug-resistant cells through single-cell RNA sequencing data, identify the set of ferrodysfunction drivers and inhibitory genes, and combine cluster analysis and enrichment score calculation to predict drug response status and degree of sensitization.
Effectively identify the drug resistance mechanism of JQ1, screen out potential sensitization drugs, provide new treatment pathways for patients with triple-negative breast cancer, and improve drug response levels and sensitization potential.
Smart Images

Figure CN118380163B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of intelligent medical treatment, and more specifically, to a method, system, device, medium and program product for predicting drug resistance status. Background Art
[0002] Triple-negative breast cancer (TNBC) is a molecular subtype of breast cancer. In preclinical and clinical experiments, BET bromodomain inhibitors (BBDIs) are considered as potential new candidates for the treatment of TNBC. JQ1, as a classic BBDI, can block the communication of BRD4 and the transcription of downstream oncogenes, thereby killing tumor cells. However, the clinical application of JQ1 has been limited by the development of drug resistance, so understanding the potential mechanism of BBDI resistance will help the treatment of cancer.
[0003] Due to the huge heterogeneity of TNBC, the genomic diversity and transcriptional heterogeneity between different patients (inter-tumor) or within the same patient (intra-tumor) can lead to different drug responses in cells. Multiple resistance mechanisms pose a major challenge to cancer treatment. Currently, single-cell RNA sequencing (scRNA-seq) technology provides an opportunity to explore the heterogeneity of drug response at single-cell resolution. scRNA-seq analysis of TNBC cells is expected to reveal the heterogeneity of BBDI resistance, which is crucial to advancing personalized treatment strategies. Summary of the invention
[0004] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention aims at the scientific problem that BET bromodomain inhibitors (BBDI) produce drug resistance during the treatment of triple-negative breast cancer (TNBC), identifies its drug resistance mechanism and screens sensitizing drugs. This study clarifies the drug resistance mechanism of JQ1, identifies potential drugs that sensitize JQ1, and provides a new approach for the treatment of patients with triple-negative breast cancer.
[0005] The first aspect of the present application discloses a method for constructing a JQ1 drug resistance status prediction model, the method comprising:
[0006] 101, obtain single-cell sequencing data of JQ1-sensitive and -resistant cell lines;
[0007] 102, preprocessing the single cell sequencing data to obtain JQ1 drug resistance differentially expressed genes;
[0008] 103, to obtain ferroptosis driver and suppressor gene sets;
[0009] 104, taking the intersection of the JQ1 resistance differentially expressed genes and the ferroptosis driving and inhibiting gene sets to obtain N JQ1 resistance-related ferroptosis genes; N is a natural number greater than or equal to 1;
[0010] 105. If the JQ1 resistance-related ferroptosis gene belongs to a ferroptosis inhibitory gene, the expression value of the gene is multiplied by the value A to obtain the product; if the JQ1 resistance-related ferroptosis gene belongs to a ferroptosis driving gene, the expression value of the gene is multiplied by the value B to obtain the product, and then the products obtained for each gene are added together to obtain the drug resistance status prediction model. Optionally, A is 1 and B is -1;
[0011] In some embodiments, the JQ1 resistance-related ferroptosis gene includes any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1;
[0012] Optionally, the formula of the drug resistance status prediction model is:
[0013]
[0014] Where n is the number of ferroptosis genes associated with JQ1 resistance; if gene i is a ferroptosis inhibitory gene, then ; If gene i is a driver gene of ferroptosis, ; is the expression value of the gene;
[0015] Optionally, the preprocessing includes: eliminating genes expressed in less than N (3) cells, filtering low-quality cells, and screening the JQ1 resistance differentially expressed genes with a first threshold;
[0016] The second aspect of the present application discloses a method for predicting drug resistance status, the method comprising:
[0017] 201, obtaining the expression value of the ferroptosis gene related to JQ1 drug resistance of the sample to be tested;
[0018] 202, inputting the expression value of the JQ1 resistance-related ferroptosis gene into a drug resistance status prediction model, and calculating the predicted value of the JQ1 resistance-related ferroptosis gene for predicting drug response; the drug resistance status prediction model is the model disclosed in the first aspect of the present application;
[0019] 203, predicting the drug resistance status of the sample to be tested to JQ1 based on the predicted value;
[0020] Optionally, the JQ1 resistance-related ferroptosis gene includes any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; Optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; Optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; Optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1;
[0021] Optionally, after 201, the method further includes: performing cluster analysis based on the gene expression values to obtain the subgroup type to which the sample to be tested belongs, and obtaining the drug resistance status of the sample to be tested to JQ1 according to the subgroup type;
[0022] Optionally, if the subgroup type is R3, a result of drug response status resistance is obtained; if the subgroup type is R5, a result of drug response status sensitivity is obtained;
[0023] Optionally, the JQ1 resistance-related ferroptosis genes include any one or more of the following: GPX4, FTH1, FTL;
[0024] Optionally, the subgroup type to which the sample to be tested belongs is the R3 subgroup, showing high expression levels of FTH1 and FTL; the subgroup type to which the sample to be tested belongs is the R5 subgroup, showing low expression levels of GPX4, FTH1, and FTL; the subgroup type to which the sample to be tested belongs is the R1 subgroup, showing high expression level of GPX4;
[0025] Optionally, the subgroup type is obtained by the following method:
[0026] Obtain single-cell sequencing data of the JQ1 drug-resistant cell line (SUM159);
[0027] Screening and processing the single-cell sequencing data to obtain M highly variable genes (HVGs); M is a natural number greater than or equal to 1, preferably 2000;
[0028] Performing dimensionality reduction analysis and unsupervised cluster analysis on the highly variable gene sequence to obtain different drug-resistant subgroups;
[0029] Performing cluster analysis on the JQ1-resistant cells, using cluster profile scores to determine the optimal resolution, and obtaining the subpopulation type;
[0030] Optionally, the method further comprises: calculating the drug response of JQ1 of different subpopulations using a drug resistance status prediction model;
[0031] Optionally, the method further comprises: identifying pathways enriched in drug-resistant subpopulations and calculating gene set enrichment scores; evaluating the differences in pathway scores between each subpopulation and other subpopulations, and identifying significantly upregulated pathways.
[0032] The third aspect of the present application discloses a method for constructing a model for predicting JQ1 sensitizing drugs, the method comprising:
[0033] 301, obtain gene expression profile data of small molecule drug perturbation experiments;
[0034] 302, screening and obtaining a small molecule drug that meets the requirements from the gene expression profile data;
[0035] 303, calculating the enrichment score NES of the JQ1 resistance-related ferroptosis gene;
[0036] 304. For small molecule drugs in which both JQ1 resistance-related ferroptosis suppressor genes and driver genes are significantly enriched, calculating the reversal score of the JQ1 resistance-related ferroptosis gene, and obtaining the drug sensitization prediction model;
[0037] Optionally, the reversal score in 304 is calculated by the following method: when the enrichment score of the drug resistance-related ferroptosis suppressor gene (NESup) is positive and the enrichment score of the drug resistance-related ferroptosis driver gene (NESdown) is negative, or when NESup is negative and NESdown is positive, subtract NESdown from NESup and then take the average of the results, and the average is the reversal score; when the enrichment score of the drug resistance-related ferroptosis suppressor gene (NESup) and the enrichment score of the drug resistance-related ferroptosis driver gene (NESdown) are both positive or both negative, the reversal score is 0;
[0038] In a fourth aspect, the present application discloses a method for predicting the drug sensitization degree of JQ1, the method comprising:
[0039] 401, obtaining gene expression profile data of the small molecule drug to be tested;
[0040] 402, calculate the enrichment score of ferroptosis genes associated with JQ1 resistance;
[0041] 403, inputting the enrichment score into a drug sensitization prediction model to calculate the reversal score of JQ1 resistance-related ferroptosis genes;
[0042] 404 , predicting the drug sensitization degree of the small molecule drug to be tested to JQ1 based on the reversal score.
[0043] Optionally, the JQ1 resistance-related ferroptosis genes include any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; Optionally, the JQ1 resistance-related ferroptosis genes also include any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; Optionally, the JQ1 resistance-related ferroptosis genes also include any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; Optionally, the JQ1 resistance-related ferroptosis genes also include any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1.
[0044] In a fifth aspect, the present application discloses a system for predicting drug resistance status, the system comprising:
[0045] The first acquisition module is used to obtain the expression value of the ferroptosis gene related to JQ1 drug resistance of the sample to be tested;
[0046] A first calculation module is used to input the expression value of the JQ1 resistance-related ferroptosis gene into a drug resistance status prediction model to calculate the predicted value of the JQ1 resistance-related ferroptosis gene for predicting drug response; the drug resistance status prediction model is the model disclosed in the first aspect of the present application;
[0047] The first prediction module is used to predict the drug resistance state of the sample to be tested to JQ1 based on the prediction value.
[0048] In a sixth aspect, the present application discloses a system for predicting the drug sensitization degree of JQ1, the system comprising:
[0049] The second acquisition module is used to obtain the gene expression profile data of the small molecule drug in the sample to be tested;
[0050] The second calculation module is used to calculate the enrichment score of ferroptosis genes associated with JQ1 resistance;
[0051] The third calculation module is used to input the enrichment score into the drug sensitization prediction model to calculate the reversal score of the ferroptosis gene associated with JQ1 resistance;
[0052] The second prediction module is used to predict the drug sensitization degree of the small molecule drug to be tested to JQ1 based on the reversal score.
[0053] The seventh aspect of the present application discloses a computer device, comprising: a memory, a processor and a computer program stored in the memory, wherein the processor executes the computer program to implement the steps of the method described in the first, second, third and fourth aspects of the present application.
[0054] In an eighth aspect, the present application discloses a computer-readable storage medium having a computer program stored thereon. When the computer program is executed by a processor, the steps of the methods described in the first, second, third and fourth aspects of the present application are implemented.
[0055] Beneficial effects of the present invention:
[0056] 1. This application creatively discloses a method for constructing a JQ1 drug resistance prediction model, which scores JQ1 resistance-related ferroptosis genes, predicts the drug response state of cells to JQ1 based on the scoring results, and verifies through experiments that the model can effectively reflect the drug response level of JQ1. In clinical applications, the model can effectively predict the drug resistance state of the sample to be tested.
[0057] 2. This application creatively discloses a method for constructing a model for predicting JQ1 sensitization drugs, through which the reversal of JQ1 resistance-related ferroptosis genes can be effectively evaluated. For small molecule drugs that are significantly enriched in both JQ1 resistance-related ferroptosis suppressor genes and driver genes, the JQ1 resistance-related ferroptosis gene reversal score (WTCS) is calculated. This score reflects the degree of sensitization to JQ1. The smaller the WTCS score, the stronger the sensitization potential to JQ1. In clinical applications, the degree of reversal of the expression of these 20 ferroptosis-related genes by candidate drugs is calculated, and drugs with high reversal degrees and low cytotoxicity are screened to achieve sensitization to JQ1.
[0058] 3. The present application also conducted an in-depth study on the resistance heterogeneity of drug-resistant cells and found that drug-resistant cells can be further divided into five subgroups. Through in-depth analysis of the drug-resistant subgroups, it was found that they were at different stages of the evolution of drug resistance and had different drug responses to JQ1. Therefore, the inventors preliminarily proposed that the drug resistance status of the sample to be tested to JQ1 can be obtained based on the subgroup type to which the sample to be tested belongs and the FR20 score.
[0059] In summary, the present invention aims at the scientific problem that BET bromodomain inhibitor (BBDI) produces drug resistance during the treatment of triple-negative breast cancer (TNBC), identifies its resistance mechanism and screens sensitizing drugs. This study clarifies the resistance mechanism of JQ1 and identifies potential drugs that sensitize JQ1, providing a new approach for the treatment of patients with triple-negative breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0060] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.
[0061] Figure 1 is a schematic diagram of a method flow chart provided by the first aspect of an embodiment of the present invention;
[0062] Figure 2 is a schematic diagram of a method flow chart provided by the second aspect of an embodiment of the present invention;
[0063] Figure 3 is a schematic diagram of a method flow chart provided by the third aspect of an embodiment of the present invention;
[0064] Figure 4 is a schematic diagram of a method flow chart provided by the fourth aspect of an embodiment of the present invention;
[0065] Figure 5 is a schematic flow chart of a system provided by a fifth aspect of an embodiment of the present invention;
[0066] Figure 6 is a schematic flow chart of a system provided by a sixth aspect of an embodiment of the present invention;
[0067] Figure 7 is a schematic diagram of a computer device provided by a seventh aspect of an embodiment of the present invention;
[0068] Figure 8 : is a schematic diagram of identifying JQ1 resistance-related ferroptosis genes provided in an embodiment of the present invention; wherein, Figure 8 A. Volcano plot of JQ1 drug resistance differential expression; the area to the right of the right dotted line indicates significantly upregulated drug resistance differential expression genes; the area to the left of the left dotted line indicates significantly downregulated drug resistance differential expression genes. The gene names of drug resistance-related ferroptosis genes are marked in the figure. Figure 8 B. Functions of differentially expressed genes in JQ1 resistance. Ferroptosis is marked with an asterisk;
[0069] Fig. 9 FR20 algorithm verification diagram provided by an embodiment of the present invention; wherein, Fig. 9 A. Box plot of FR20 scores of JQ1-sensitive and -resistant cells in single-cell sequencing data of the SUM159 cell line. Fig. 9 B. Box plot of FR20 scores of JQ1-sensitive and -resistant cells in single-cell sequencing data of the SUM149 cell line. Fig. 9C. Box plot of FR20 scores of JQ1-sensitive and -resistant cells in the next-generation gene sequencing data of SUM159 and SUM149 cell lines. Fig. 9 D. Box plot of FR20 scores of JQ1-sensitive and -resistant cells in gene expression chip data of H23 and H1975 cell lines. Fig. 9 E. Bar graph of the average FR20 scores of JQ1-sensitive and -resistant cells in the next-generation gene sequencing data of 22RV1 and LNCaP cell lines. Fig. 9 F. Box plot of AUC values of high and low FR20 score cells in CCLE's next-generation gene sequencing data and GDSC's gene expression chip data. ****: p < 0.0001, ***: p < 0.001; **: p < 0.01; *: p < 0.05;
[0070] Fig.10 Schematic diagram of the D-FR20 algorithm for predicting JQ1 sensitizing drugs provided by an embodiment of the present invention; wherein, Fig.10 A. Schematic diagram of the D-FR20 algorithm. Fig.10 B. The top 10 predicted JQ1 sensitizing drugs;
[0071] Fig.11 is a schematic diagram of identifying drug-resistant subpopulations provided by an embodiment of the present invention; wherein, Fig.11 A. Plot of the average silhouette coefficient at each resolution. Fig.11 B. UMAP visualization of drug-resistant cells at 0.4 resolution;
[0072] Fig.12 Schematic diagram of heterogeneity of JQ1 drug-resistant subpopulations provided in an embodiment of the present invention; wherein, Fig.12 A. Box plot of FR20 scores in five resistant subpopulations. Fig.12 B. Box plot of the half-maximal inhibitory concentration (IC50) of the five drug-resistant subpopulations predicted by CaDRReS-Sc. Fig.12 C. Box plot of CytoTRACE scores for the five resistant subpopulations. Fig.12 D. Lineage trajectories of drug-resistant subpopulations inferred by Monocle2. Cells are labeled by subpopulation (top) or pseudotime (bottom). Fig.12 E. CytoTRACE analysis of the five subpopulations in Figure 1. Cells were labeled by CytoTRACE score (top) or subpopulation (bottom). Fig.12 F. Heat map of JQ1 resistance-related ferroptosis gene expression in the resistant subpopulation. Fig.12 G. Ridge plots of GPX4, FTL, and FTH1 expression in the resistant subpopulation. Fig.12H. The top five KEGG pathways significantly and specifically enriched in each drug-resistant subgroup. DETAILED DESCRIPTION
[0073] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.
[0074] In some of the processes described in the specification and claims of the present invention and the above-mentioned figures, multiple operations that appear in a specific order are included, but it should be clearly understood that these operations may not be executed in the order in which they appear in this article or executed in parallel. The serial numbers of the operations, such as 101, 102, etc., are only used to distinguish different operations, and the serial numbers themselves do not represent any execution order. In addition, these processes may include more or fewer operations, and these operations may be executed in sequence or in parallel. It should be noted that the descriptions of "first", "second", etc. in this article are used to distinguish different messages, devices, modules, etc., do not represent the order of precedence, and do not limit the "first" and "second" to be different types.
[0075] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0076] Figure 2 The present invention provides a method for predicting drug resistance status, which includes the following steps:
[0077] 201: Obtain the expression value of the ferroptosis gene related to JQ1 drug resistance of the sample to be tested;
[0078] In one embodiment, the term "subject" or "person to be tested" or "sample to be tested" as used herein refers to any animal (e.g., mammal), including but not limited to humans, non-human primates, rodents, etc., which will be the recipient of a specific treatment. Generally, the terms "subject" and "patient" are used interchangeably herein when referring to a human subject. Preferably, the subject is a human.
[0079] In one embodiment, the sample to be tested is a patient undergoing clinical prognosis assessment.
[0080] Optionally, the JQ1 resistance-related ferroptosis gene includes any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; Optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; Optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; Optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1;
[0081] In one embodiment, after 201, the method further includes: obtaining the subgroup type to which the sample to be tested belongs based on the expression value of the ferroptosis gene related to JQ1 resistance, and obtaining the drug resistance status of the sample to be tested to JQ1 according to the subgroup type; the subgroup type is obtained by clustering analysis of the gene expression value.
[0082] Optionally, if the subgroup type is R3 (R3 subgroup FR20 score is high), the result of drug response status resistance is obtained; if the subgroup type is R5 (R5 subgroup FR20 score is low), the result of drug response status sensitivity is obtained;
[0083] Optionally, the JQ1 resistance-related ferroptosis genes include any one or more of the following: GPX4, FTH1, FTL;
[0084] Optionally, if the expression levels of FTH1 and FTL are high, the subgroup type to which the sample to be tested belongs is the R3 subgroup (the study shows that the R3 subgroup shows high expression levels of FTH1 and FTL); if the expression levels of GPX4, FTH1, and FTL are low, the subgroup type to which the sample to be tested belongs is the R5 subgroup (the study shows that the R5 subgroup shows low expression levels of GPX4, FTH1, and FTL); if the expression level of GPX4 is high, the subgroup type to which the sample to be tested belongs is the R1 subgroup (the study shows that the R1 subgroup shows high expression level of GPX4);
[0085] Optionally, the R1 subgroup is enriched in the Jak-STAT signaling pathway and the Notch signaling pathway, the R3 subgroup is enriched in the alpha-linolenic acid metabolism and ErbB signaling pathways, and the R5 subgroup is enriched in the neurotrophin signaling pathway;
[0086] Optionally, the subgroup type is obtained by the following method:
[0087] Obtain single-cell sequencing data of the JQ1 drug-resistant cell line (SUM159);
[0088] Screening and processing the single-cell sequencing data to obtain M highly variable genes (HVGs); M is a natural number greater than or equal to 1, preferably 2000;
[0089] Performing dimensionality reduction analysis and unsupervised cluster analysis on the highly variable gene sequence to obtain different drug-resistant subgroups;
[0090] The JQ1 drug-resistant cells are clustered and analyzed, and the optimal resolution is determined using the clustering profile score to obtain the subpopulation type; the resolution needs to be specified in unsupervised clustering, so the clustering profile score is used to determine the optimal resolution; the JQ1 drug-resistant cells refer to the drug-resistant cells in step 101;
[0091] Optionally, the screening process includes: removing genes expressed in less than 3 cells and filtering low-quality cells; Optionally, filtering low-quality cells includes: filtering cells with less than 200 genes or mitochondrial genes accounting for more than 20%;
[0092] Optionally, the method further comprises: calculating the drug response of JQ1 of different subpopulations using a drug resistance status prediction model;
[0093] Optionally, the method further comprises: identifying differentially expressed genes (DEGs); inferring the pedigree relationship between JQ1 resistant subpopulations and constructing pseudo-trajectories of resistant subpopulations;
[0094] Optionally, the method further comprises: identifying pathways enriched in the drug-resistant subgroups, calculating gene set enrichment scores; evaluating the differences in pathway scores between each subgroup and other subgroups, and identifying significantly upregulated pathways. Subgroup analysis is related to the application of the FR20 algorithm.
[0095] 202: inputting the expression value of the JQ1 resistance-related ferroptosis gene into a drug resistance status prediction model, and calculating the predicted value of the JQ1 resistance-related ferroptosis gene for predicting drug response;
[0096] In one embodiment, Figure 1 As shown, the method for constructing the drug resistance status prediction model includes:
[0097] 101, obtain single-cell sequencing data of JQ1-sensitive and -resistant cell lines;
[0098] 102, preprocessing the single cell sequencing data to obtain JQ1 drug resistance differentially expressed genes;
[0099] 103, to obtain ferroptosis driver and suppressor gene sets;
[0100] 104, taking the intersection of the JQ1 resistance differentially expressed genes and the ferroptosis driving and inhibiting gene sets to obtain N JQ1 resistance-related ferroptosis genes; N is a natural number greater than or equal to 1;
[0101] 105. If the JQ1 resistance-related ferroptosis gene belongs to a ferroptosis inhibitory gene, the expression value of the gene is multiplied by the value A to obtain the product. If the JQ1 resistance-related ferroptosis gene belongs to a ferroptosis driving gene, the expression value of the gene is multiplied by the value B to obtain the product. Then, the products obtained for each gene are added together to obtain the drug resistance status prediction model; the drug resistance status prediction model is the FR20 algorithm. The value predicted by the drug resistance status prediction model (FR20 algorithm) is a relative value, and the larger the value, the more drug-resistant it is. For example, the predicted value is calculated for sample one and sample two. If the predicted value of sample one is greater than the predicted value of sample two, then sample one is more resistant than sample two. The drug response status is classified into two categories: sensitive and resistant. Optionally, A is 1 and B is -1;
[0102] In some embodiments, the JQ1 resistance-related ferroptosis gene includes any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; optionally, the JQ1 resistance-related ferroptosis gene also includes any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1;
[0103] Optionally, the formula of the drug resistance status prediction model is:
[0104]
[0105] Where n is the number of ferroptosis genes associated with JQ1 resistance; if gene i is a ferroptosis inhibitory gene, then ; If gene i is a driver gene of ferroptosis, ; is the expression value of the gene.
[0106] Optionally, the preprocessing includes: eliminating genes expressed in less than N (3) cells, filtering low-quality cells, and screening the JQ1 resistance differentially expressed genes with a first threshold;
[0107] Optionally, filtering low-quality cells includes: filtering cells with less than 200 genes or cells in which mitochondrial genes account for more than 20%;
[0108] Optionally, the first threshold is |log2FC| > 0.25 and FDR < 0.01;
[0109] Optionally, after filtering low-quality cells and before screening with the first threshold, the method further includes: standardization processing.
[0110] In one embodiment, after step 102, the method further comprises: performing functional enrichment analysis on the JQ1 drug-resistant differentially expressed genes.
[0111] 203: predicting the drug resistance status of the sample to be tested to JQ1 based on the predicted value;
[0112] like Figure 4 FIG. 1 is a flow chart of a method for predicting the drug sensitization degree of JQ1 provided by an embodiment of the present invention, wherein the method comprises:
[0113] 401, obtaining gene expression profile data of the small molecule drug to be tested;
[0114] 402, calculating the enrichment score of the JQ1 resistance-related ferroptosis gene;
[0115] 403, inputting the enrichment score into a drug sensitization prediction model to calculate the reversal score of JQ1 resistance-related ferroptosis genes;
[0116] 404 , predicting the drug sensitization degree of the small molecule drug to be tested to JQ1 based on the reversal score.
[0117] Optionally, the JQ1 resistance-related ferroptosis genes include any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; Optionally, the JQ1 resistance-related ferroptosis genes also include any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; Optionally, the JQ1 resistance-related ferroptosis genes also include any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; Optionally, the JQ1 resistance-related ferroptosis genes also include any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1.
[0118] In some embodiments, Figure 3 As shown, the method for constructing the drug sensitization prediction model includes:
[0119] 301, obtain gene expression profile data of small molecule drug perturbation experiments;
[0120] 302, screening and obtaining a small molecule drug that meets the requirements from the gene expression profile data;
[0121] 303, calculating the enrichment score NES of the JQ1 resistance-related ferroptosis gene; the ferroptosis gene refers to: a ferroptosis inhibitory gene set and a driver gene set;
[0122] 304. For small molecule drugs that are significantly enriched in both JQ1 resistance-related ferroptosis suppressor genes and driver genes, calculate the reversal score of the JQ1 resistance-related ferroptosis gene to obtain the drug sensitization prediction model; because small molecule drugs can reverse the expression of ferroptosis suppressor genes and driver genes;
[0123] Optionally, the reversal score in 304 is calculated by the following method: when the enrichment score (NESup) of the resistance-related ferroptosis suppressor gene is positive and the enrichment score (NESdown) of the resistance-related ferroptosis driver gene is negative, or when NESup is negative and NESdown is positive, subtract NESdown from NESup and take the average of the results, and the average is the reversal score; when the enrichment score (NESup) of the resistance-related ferroptosis suppressor gene and the enrichment score (NESdown) of the resistance-related ferroptosis driver gene are both positive or both negative, the reversal score is 0; the reversal score in the present application can take a negative value, and our screening goal is to find small molecule drugs with the smallest negative value.
[0124] Optionally, the formula of the drug sensitization degree prediction model is:
[0125]
[0126] in, represents the enrichment score of drug resistance-related ferroptosis suppressor genes; It represents the enrichment score of drug resistance-related ferroptosis driver genes; the smaller the WTCS score, the stronger the sensitization potential to JQ1; the drug sensitization degree prediction model is the D-FR20 algorithm.
[0127] Optionally, the gene expression profile data comes from the LINCS database; LINCS (The Library of Integrated Network-Based Cellular Signatures) is a database under the NIH that perturbs cells in various ways (such as knocking out or overexpressing certain genes, but mainly the effects of drugs on cells), and then compares cell expression profiles or other cell processes before and after the cell perturbation.
[0128] Optionally, in 303, the GSEA method is used to calculate the enrichment score, and significantly enriched small molecule drugs are screened through 1000 random perturbations, and the screening threshold is FDR<0.05.
[0129] In some embodiments, there are 12 ferroptosis driving genes among the above-mentioned ferroptosis genes, including: ACSL4, ATF4, ATG3, BID, HIF1A, HMGB1, HMOX1, LIFR, MTDH, PGRMC1, SNCA, VDAC2; there are 8 inhibitory genes, including: AKR1C2, AKR1C3, ALDH3A2, FTH1, GPX4, G6PD, FTL, NQO1.
[0130] Figure 5 A system for predicting drug resistance status provided by an embodiment of the present invention comprises:
[0131] The first acquisition module 501 is used to obtain the expression value of the ferroptosis gene related to JQ1 drug resistance of the sample to be tested;
[0132] A first calculation module 502 is used to input the expression value of the JQ1 resistance-related ferroptosis gene into a drug resistance state prediction model to calculate the predicted value of the JQ1 resistance-related ferroptosis gene for predicting drug response;
[0133] The first prediction module 503 is used to predict the drug resistance state of the sample to be tested to JQ1 based on the predicted value.
[0134] Figure 6 An embodiment of the present invention also provides a system for predicting the drug sensitization degree of JQ1, the system comprising:
[0135] The second acquisition module 601 is used to acquire the gene expression profile data of the small molecule drug in the sample to be tested;
[0136] The second calculation module 602 is used to calculate the enrichment score of the JQ1 resistance-related ferroptosis gene;
[0137] The third calculation module 603 is used to input the enrichment score into the drug sensitization prediction model to calculate the reversal score of the ferroptosis gene associated with JQ1 resistance;
[0138] The second prediction module 604 is used to predict the drug sensitization degree of the small molecule drug to be tested to JQ1 based on the reversal score.
[0139] Figure 7A computer device provided by an embodiment of the present invention comprises: a memory, a processor and a computer program stored in the memory, wherein the processor executes the computer program to implement the steps of the method described in the first, second, third and fourth aspects of the present application.
[0140] The embodiment of the present invention also provides a computer-readable storage medium having a computer program stored thereon, and when the computer program is executed by a processor, the steps of the methods of the first, second, third and fourth aspects of the present application are implemented.
[0141] An embodiment of the present invention further discloses a computer program product, including a computer program, which implements the steps of the methods of the first, second, third and fourth aspects of the present application when executed by a processor.
[0142] Example 1: Model construction process for predicting the degree of JQ1 drug response
[0143] 1.1 Experimental Materials
[0144] Single-cell sequencing data (scRNA-seq) of JQ1-sensitive and -resistant SUM159 cell lines.
[0145] 1.2 Experimental methods
[0146] (1) Seurat R package (version 4.3.0) was used for quality control and downstream analysis. Genes expressed in less than 3 cells were removed; low-quality cells were also filtered out: cells with less than 200 genes or mitochondrial genes accounting for more than 20% were filtered out.
[0147] (2) The data was normalized using the NormalizeData function.
[0148] (3) The FindMarkers function was used to identify JQ1 resistance differentially expressed genes (DEGs), with the specific thresholds of |log2FC| > 0.25 and FDR < 0.01.
[0149] (4) Metascape online platform was used to perform functional enrichment analysis on JQ1 resistance differentially expressed genes and visualize the results.
[0150] (5) Ferroptosis driver and inhibitory genes were downloaded from the FerrDb V2 database.
[0151] (6) The intersection of JQ1 resistance differentially expressed genes and ferroptosis driver and inhibitor genes was taken to identify 20 ferroptosis genes related to JQ1 resistance. The FR20 algorithm was further used to integrate the expression of these genes to predict the cell response to JQ1. The specific formula is as follows:
[0152]
[0153] n is the number of ferroptosis genes associated with JQ1 resistance; if gene i is a ferroptosis inhibitory gene, then ; If gene i is a driver gene of ferroptosis, ; is the expression value of the gene.
[0154] 1.3 Experimental Results
[0155] Differentially expressed genes for JQ1 resistance Figure 8 As shown in A, the functional enrichment analysis results of JQ1 drug resistance differentially expressed genes ( Figure 8 B) shows that ferroptosis function is closely related to JQ1 resistance. This study identified 20 ferroptosis genes associated with JQ1 resistance, including 12 ferroptosis driver genes (ACSL4, ATF4, ATG3, BID, HIF1A, HMGB1, HMOX1, LIFR, MTDH, PGRMC1, SNCA, VDAC2) and 8 inhibitory genes (AKR1C2, AKR1C3, ALDH3A2, FTH1, GPX4, G6PD, FTL, NQO1) associated with JQ1 resistance.
[0156] Example 2: Verification of FR20 Scoring Algorithm
[0157] 1.1 Experimental Materials
[0158] The accuracy of the FR20 algorithm is verified by 10 sets of data, as shown in Table 1, including the following data:
[0159] (1) Single-cell sequencing data (scRNA-seq) of JQ1-sensitive and -resistant SUM159 and SUM149 cell lines.
[0160] (2) Next-generation gene sequencing data (RNA-seq) of JQ1-sensitive and -resistant SUM159, SUM149, 22RV1, and LNCaP cell lines.
[0161] (3) Gene expression chip data (microarray) of JQ1-sensitive and -resistant H23 and H1975 cell lines.
[0162] (4) Next-generation gene sequencing data (RNA-seq) of cancer cell lines included in the CCLE project.
[0163] (5) Gene expression chip data (microarray) of cancer cell lines included in the GDSC project.
[0164] Table 1. Summary of validation data cohorts used by FR20
[0165]
[0166] Note: Validation Cohort: validation cohort; Dataset: dataset; Data Source: data source; Samples: samples; Data Type: data type.
[0167] 1.2 Experimental methods
[0168] (1) For the single-cell sequencing data of SUM159 and SUM149 cell lines, the FR20 scores of JQ1-sensitive and -resistant cells were compared using a one-sided rank sum test.
[0169] (2) For the next-generation gene sequencing data of SUM159 and SUM149 and the gene expression chip data of H23 and H1975 cell lines, the FR20 scores of JQ1-sensitive and -resistant cells were compared using a one-sided T test.
[0170] (3) For the next-generation gene sequencing data of 22RV1 and LNCaP cell lines, the average FR20 scores of JQ1-sensitive and -resistant cells were compared.
[0171] (4) Download drug response data of cancer cell lines from the CTRP project. For the next-generation gene sequencing data of cancer cell lines in CCLE and the gene expression chip data of cancer cell lines in GDSC, first calculate the FR20 score of the cell line, then extract the cell lines with the highest upper quartile and the lowest lower quartile of FR20 scores in CCLE and GDSC respectively and divide them into high and low FR20 score groups. Next, obtain the true drug response curve area (AUC value) of these cell lines (from the CTRP project). The AUC values of the high and low FR20 score groups were compared by a one-sided rank sum test.
[0172] 1.3 Experimental Results
[0173] The FR20 scores of the drug-resistant group in all individual cell line data were higher than those of the sensitive group ( Fig. 9 The AUC score of the pan-cancer cell line high FR20 score group was higher than that of the low FR20 score group ( Fig. 9 These results suggest that FR20 can effectively reflect the drug response level of JQ1.
[0174] Example 3: Model construction process for predicting JQ1 sensitizing drugs
[0175] 1.1 Experimental Materials
[0176] The gene expression profile data of small molecule drug perturbation experiments were downloaded from the LINCS database.
[0177] 1.2 Experimental methods
[0178] For each small molecule drug perturbation experiment, the D-FR20 algorithm was used to evaluate the reversal of JQ1 resistance-related ferroptosis genes. Specifically, the enrichment scores (NES) of JQ1 resistance-related ferroptosis suppressor genes and driver genes were calculated by the GSEA method. Through 1000 random perturbations, significantly enriched small molecule drugs were screened (FDR < 0.05). For small molecule drugs that were significantly enriched in both JQ1 resistance-related ferroptosis suppressor genes and driver genes, the JQ1 resistance-related ferroptosis gene reversal score (WTCS) was calculated. This score reflects the degree of sensitization to JQ1. The specific formula is as follows:
[0179]
[0180] in, represents the enrichment score of drug resistance-related ferroptosis suppressor genes; Represents the enrichment score of drug resistance-related ferroptosis driver genes. The smaller the WTCS score, the stronger the sensitization potential to JQ1.
[0181] 1.3 Experimental Results
[0182] Based on the previously identified resistance-related ferroptosis genes, we proposed an algorithm, D-FR20, to identify JQ1-sensitizing drugs based on the gene expression of 20 ferroptosis genes. Here, we focus on small molecules that can effectively reduce the expression of JQ1 resistance-related ferroptosis inhibitors and upregulate the expression of JQ1 resistance-related ferroptosis driver genes. The D-FR20 algorithm is shown in the figure below. Fig.10 As shown in A in the figure: The gene expression profile data of 720,216 small molecule drugs were obtained from the gene expression profile data of the small molecule drug perturbation experiment, and the standardized enrichment scores NES of ferroptosis inhibitory genes (shown as inhibitors) and ferroptosis driving genes (shown as drivers) were calculated. For ferroptosis inhibitory genes (shown as inhibitors) and ferroptosis driving genes (shown as drivers), significantly enriched small molecules (FDR < 0.05) were retained, and the resensitization level of small molecules was reflected based on the WTCS (weighted connectivity score) score, and candidate small molecule drugs were screened according to the level; the D-FR20 algorithm was used to discover potential drugs that can reverse JQ1 resistance, and to study whether the upregulated ferroptosis inhibitors (or downregulated ferroptosis driving factors) are enriched at the bottom (or top) of the order of drug perturbation; the top 10 drugs screened out are as follows: Fig.10As shown in Figure B, among the top 10 candidate small molecule drugs, 50% of the drugs have been reported to have anti-cancer or anti-cancer potential. When focusing on the top 5 candidate drugs, this proportion is further increased to 80%. These results illustrate the effectiveness of D-FR20.
[0183] Example 4: Construction process of JQ1 drug-resistant cell subpopulation classification model
[0184] 1.1 Experimental Materials
[0185] Single-cell sequencing data of the JQ1-resistant SUM159 cell line.
[0186] 1.2 Experimental methods
[0187] Quality control and downstream analyses were performed using the Seurat R package (version 4.3.0):
[0188] (1) Genes expressed in less than 3 cells were eliminated; low-quality cells were filtered out: cells with less than 200 genes or mitochondrial genes accounting for more than 20% were filtered out.
[0189] (2) The data was normalized using the NormalizeData function.
[0190] (3) 2000 highly variable genes (HVGs) were selected using the FindVariableGenes function. Principal component analysis (PCA) was performed on the first 10 dimensions and then visualized using the unified manifold approximation and projection (UMAP).
[0191] (4) Unsupervised clustering analysis was performed using the FindClusters function.
[0192] (5) To explore the heterogeneity of drug-resistant cells, cluster analysis was performed on JQ1-resistant cells, and the optimal resolution was determined using the cluster profile score.
[0193] (6) Differentially expressed genes (DEGs) were identified using the FindMarkers function and the criteria of |log2FC| > 0.25 and FDR < 0.01 were set.
[0194] (7) Monocle2 (version 2.18.0) was used to infer the phylogenetic relationships between JQ1 resistant subpopulations. The “root” (starting point) of the evolutionary process was predicted by CytoTRACE. To obtain the starting point of the resistant subpopulation, the CytoTRACE and Monocle2 algorithms with their default parameters were used to construct pseudotrajectories of the resistant subpopulations.
[0195] (8) To compare the enriched KEGG pathways in the drug-resistant subgroups, the ssGSEA method was used to calculate the gene set enrichment score. The difference in pathway scores between each subgroup and all other subgroups was evaluated by a one-sided rank sum test, and significantly upregulated pathways were identified (p < 0.05).
[0196] (9) The FR20 algorithm was used to calculate the drug response of JQ1 in different subgroups.
[0197] 1.3 Experimental Results
[0198] We further performed cluster analysis on the drug-resistant cells, selected appropriate profile scores and obtained five subpopulations ( Fig.11 A and Fig.11 Interestingly, the drug response to JQ1 was significantly different among the five subgroups (ANOVA p = 2.11×10-18). Subgroup R3 (R5) exhibited higher (lower) FR20 scores ( Fig.12 These results were further validated by the CaDRReS-Sc method ( Fig.12 Pseudo-time analysis revealed the lineage relationships of the five subpopulations ( Fig.12 C and D). By CytoTRACE, subpopulation R5 was identified as the “root” ( Fig.12 The other subgroups were located on different branches of the trajectory, indicating that they were at different stages of resistance evolution ( Fig.12 In addition, the five subpopulations showed different expression patterns of 20 ferroptosis genes ( Fig.12 In general, subpopulation R1 highly expressed GPX4 (log2FC = 0.359, p = 2.074×10-28, Fig.12 F and G) Subgroup R3 tended to express FTH1 (log2FC = 0.53, p = 8.552×10-46) and FTL (log2FC = 0.492, p = 1.121×10-36, Fig.12 Subgroup R5 tended to have lower expression of GPX4 (log2FC = -0.357, p = 2.509×10-18), FTH1 (log2FC = -0.622, p = 1.584×10-47), and FTL (log2FC = -0.561, p = 7.403×10-40, Fig.12 To further investigate the functional differences among the five subgroups, we analyzed the pathways that were specifically upregulated in the five subgroups. Fig.12H in the figure shows the pathways that are specifically enriched in each subgroup. For example, the R1 subgroup is enriched in the Jak-STAT signaling pathway and the Notch signaling pathway ( Fig.12 The H in the figure shows that the R3 subpopulation is enriched in alpha-linolenic acid metabolism and ErbB signaling pathways. These results indicate the heterogeneity of JQ1-resistant cells and the accuracy of the proposed JQ1-resistant cell subpopulation classification model.
[0199] The validation results of this validation example show that assigning intrinsic weights to indications can moderately improve the performance of the method relative to the default setting.
[0200] Those skilled in the art can clearly understand that, for the convenience and brevity of description, the specific working processes of the systems, devices and units described above can refer to the corresponding processes in the aforementioned method embodiments and will not be repeated here.
[0201] In the several embodiments provided in the present application, it should be understood that the disclosed systems, devices and methods can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or units, which can be electrical, mechanical or other forms.
[0202] The units described as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.
[0203] In addition, each functional unit in each embodiment of the present invention may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit. The above-mentioned integrated unit may be implemented in the form of hardware or in the form of software functional units.
[0204] A person skilled in the art may understand that all or part of the steps in the various methods of the above embodiments may be completed by instructing related hardware through a program, and the program may be stored in a computer-readable storage medium, and the storage medium may include: a read-only memory (ROM), a random access memory (RAM), a disk or an optical disk, etc.
[0205] A person skilled in the art can understand that all or part of the steps in the above-mentioned embodiment method can be completed by instructing related hardware through a program, and the program can be stored in a computer-readable storage medium. The above-mentioned storage medium can be a read-only memory, a disk or an optical disk, etc.
[0206] The above is a detailed introduction to a computer device provided by the present invention. For a person skilled in the art, according to the concept of the embodiments of the present invention, there may be changes in the specific implementation method and application scope. In summary, the content of this specification should not be understood as limiting the present invention.
Claims
1. A method for constructing a JQ1 drug resistance status prediction model, characterized in that: The method comprises: 101, obtain single-cell sequencing data of JQ1-sensitive and -resistant cell lines; 102, preprocessing the single cell sequencing data to obtain JQ1 drug resistance differentially expressed genes; 103, to obtain ferroptosis driver and suppressor gene sets; 104, taking the intersection of the JQ1 resistance differentially expressed genes and the ferroptosis driving and inhibiting gene sets to obtain N JQ1 resistance-related ferroptosis genes; N is a natural number greater than or equal to 1; 105. If the JQ1 resistance-related ferroptosis gene belongs to a ferroptosis inhibitory gene, the expression value of the ferroptosis gene is multiplied by the value A to obtain the product; if the JQ1 resistance-related ferroptosis gene belongs to a ferroptosis driving gene, the expression value of the ferroptosis gene is multiplied by the value B to obtain the product, and then the products obtained for each ferroptosis gene are added together to obtain the JQ1 drug resistance status prediction model; the JQ1 resistance-related ferroptosis gene includes any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A.
2. The method for constructing a JQ1 drug resistance status prediction model according to claim 1, characterized in that: The JQ1 resistance-related ferroptosis genes also include any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1; The formula of the JQ1 drug resistance status prediction model is: Where n is the number of ferroptosis genes associated with JQ1 resistance; if gene i is a ferroptosis inhibitory gene, then ; If gene i is a driver gene of ferroptosis, ; is the expression value of the gene; The preprocessing includes: eliminating genes expressed in less than N cells, filtering low-quality cells, and screening the JQ1 drug-resistant differentially expressed genes with a first threshold.
3. A method for predicting JQ1 drug resistance status, characterized in that: The method comprises: 201, obtaining the expression value of the ferroptosis gene related to JQ1 drug resistance of the sample to be tested; 202, inputting the expression value of the JQ1 resistance-related ferroptosis gene into the JQ1 drug resistance status prediction model according to claim 1 or 2, and calculating the predicted value of the JQ1 resistance-related ferroptosis gene for predicting the JQ1 drug response; 203, predicting the drug resistance state of the sample to be tested to JQ1 based on the predicted value; the predicted value is a relative value, and the predicted value of the sample to be tested is compared with the control value or the predicted value of another sample to be tested, and the larger the predicted value is, the more drug-resistant the sample is; The JQ1 resistance-related ferroptosis genes include any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: FTH1, GPX4, G6PD, FTL, NQO1; After 201, the method further includes: performing cluster analysis based on the gene expression values to obtain the subgroup type to which the sample to be tested belongs, and obtaining the drug resistance status of the sample to be tested to JQ1 according to the subgroup type; If the subgroup type is R3, the result of JQ1 drug response status resistance is obtained; if the subgroup type is R5, the result of JQ1 drug response status sensitivity is obtained; The JQ1 resistance-related ferroptosis genes include any one or more of the following: GPX4, FTH1, FTL; The subgroup type to which the sample to be tested belongs is the R3 subgroup, showing high expression levels of FTH1 and FTL; the subgroup type to which the sample to be tested belongs is the R5 subgroup, showing low expression levels of GPX4, FTH1, and FTL; the subgroup type to which the sample to be tested belongs is the R1 subgroup, showing high expression level of GPX4.
4. The method for predicting JQ1 drug resistance status according to claim 3, characterized in that: The subgroup type is obtained by the following method: Obtain single-cell sequencing data of JQ1 drug-resistant cell line; Screening and processing the single-cell sequencing data to obtain M highly variable genes, where M is a natural number greater than or equal to 1; Performing dimensionality reduction analysis and unsupervised cluster analysis on the highly variable genes to obtain different drug-resistant subgroups; The JQ1-resistant cells were subjected to cluster analysis, and the optimal resolution was determined using the cluster profile score to obtain the subpopulation type.
5. A method for constructing a JQ1 drug sensitization prediction model, characterized in that: The method comprises: 301, obtain gene expression profile data of small molecule drug perturbation experiments; 302, screening and obtaining a small molecule drug that meets the requirements from the gene expression profile data; 303, calculate the enrichment score NES of JQ1 resistance-related ferroptosis genes; 304. For small molecule drugs in which both JQ1 resistance-related ferroptosis suppressor genes and driver genes are significantly enriched, the reversal score of the JQ1 resistance-related ferroptosis gene is calculated to obtain a JQ1 drug sensitization prediction model; The reversal score in 304 is calculated by the following method: when the enrichment score of the resistance-related ferroptosis inhibitory gene is recorded as NESup as a positive value, and the enrichment score of the resistance-related ferroptosis driver gene is recorded as NESdown as a negative value, or when NESup is a negative value and NESdown is a positive value, NESup is subtracted from NESdown and the average of the results is taken, and the average value is the reversal score; when NESup and NESdown are both positive or both negative, the reversal score is 0.
6. A method for predicting the drug sensitization degree of JQ1, characterized in that: The method comprises: 401, obtaining gene expression profile data of the small molecule drug to be tested; 402, calculate the enrichment score of ferroptosis genes associated with JQ1 resistance; 403, inputting the enrichment score into the JQ1 drug sensitization prediction model of claim 5 to calculate the reversal score of the JQ1 resistance-related ferroptosis gene; 404, predicting the drug sensitization degree of the small molecule drug to be tested to JQ1 based on the reversal score; the smaller the reversal score, the stronger the sensitization potential to JQ1; The JQ1 resistance-related ferroptosis genes include any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: FTH1, GPX4, G6PD, FTL, and NQO1.
7. A system for predicting JQ1 drug resistance status, characterized in that: The system comprises: The first acquisition module is used to obtain the expression value of the ferroptosis gene related to JQ1 drug resistance of the sample to be tested; A first calculation module, for inputting the expression value of the JQ1 resistance-related ferroptosis gene into the drug resistance state prediction model according to claim 1 or 2, and calculating the predicted value of the JQ1 resistance-related ferroptosis gene for predicting drug response; A first prediction module is used to predict the drug resistance state of the sample to be tested to JQ1 based on the prediction value; the prediction value is a relative value, and the predicted value of the sample to be tested is compared with the control value or the predicted value of another sample to be tested. The larger the predicted value is, the more drug resistant it is; The JQ1 resistance-related ferroptosis genes include any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: FTH1, GPX4, G6PD, FTL, and NQO1.
8. A system for predicting the drug sensitization degree of JQ1, characterized in that: The system comprises: The second acquisition module is used to obtain the gene expression profile data of the small molecule drug to be tested; The second calculation module is used to calculate the enrichment score of ferroptosis genes associated with JQ1 resistance; A third calculation module is used to input the enrichment score into the drug sensitization prediction model according to claim 5 to calculate the reversal score of the ferroptosis gene associated with JQ1 resistance; A second prediction module is used to predict the drug sensitization degree of the small molecule drug to be tested to JQ1 based on the reversal score; the smaller the reversal score, the stronger the sensitization potential to JQ1; The JQ1 resistance-related ferroptosis genes include any one or more of the following: ACSL4, ATF4, ATG3, BID, HIF1A; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: HMGB1, HMOX1, LIFR, MTDH, PGRMC1; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: SNCA, VDAC2, AKR1C2, AKR1C3, ALDH3A2; The JQ1 resistance-related ferroptosis genes also include any one or more of the following: FTH1, GPX4, G6PD, FTL, and NQO1.
9. A computer device comprising: A memory, a processor and a computer program stored in the memory, wherein the processor executes the computer program to implement the steps of the method according to any one of claims 1 to 6.
10. A computer-readable storage medium, characterized in that: A computer program is stored thereon, and when the computer program is executed by a processor, the steps of the method described in any one of claims 1 to 6 are implemented.
